Ebb TIDES As Takeda’s Dengue Contender Weaker At 18 Months
Lower DENV-3 Efficacy A Concern?
Takeda's TAK-003 generally positive in new 18-month analysis, but efficacy falls versus 12 months and lowest effectiveness again seen against serotype 3.
You may also be interested in...
Promising data from Phase I clinical trials of a dengue vaccine and a $24.3m award by UN agencies for its Easyfive-TT pentavalent vaccine bode well for Panacea Biotec, but are they enough to turn the company’s fortunes around?
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.